Angel Aleman Marquez

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

D. Annane, T. Welte, U. Jaschinski, 2022, The Lancet Respiratory Medicine.

Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients

D. Annane, U. Jaschinski, P. van Paassen, 2023, Intensive Care Medicine Experimental.